<PAGE>
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
(Mark One)
/X/ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the quarterly period ended March 31, 2000
OR
/ / TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES
EXCHANGE ACT OF 1934
For the transition period from ________ to ___________
Commission file number: 0-21130
ENERGY BIOSYSTEMS CORPORATION
(Exact name of registrant as specified in its charter)
Delaware 04-3078857
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)
4200 Research Forest Drive
The Woodlands, Texas 77381
(address of principal executive offices) (zip code)
281-419-7000
(Registrant's telephone number, including area code)
Indicate by check mark whether the registrant (1) has filed all reports
required to be filed by Section 13 or 15(d) of the Securities Exchange Act of
1934 during the preceding 12 months (or for such shorter period that the
registrant was required to file such reports), and (2) has been subject to such
filing requirements for the past 90 days. Yes X No
--- ---
As of May 4, 2000, there were outstanding 7,020,039 shares of Common
Stock, par value $.01 per share, of the registrant.
<PAGE>
ENERGY BIOSYSTEMS CORPORATION
FORM 10-Q FOR THE QUARTER ENDED MARCH 31, 2000
INDEX
<TABLE>
<CAPTION>
Page
----
<S> <C> <C>
Factors Affecting Forward-Looking Statements 3
PART I. FINANCIAL INFORMATION
Item 1. Financial Statements 4
Balance Sheets as of March 31, 2000 (Unaudited)
and December 31, 1999 5
Statements of Operations for the Three Months
Ended March 31, 2000 and 1999 (Unaudited) 6
Statements of Cash Flows for the Three Months Ended
March 31, 2000 and 1999 (Unaudited) 7
Notes to Financial Statements 8
Item 2. Management's Discussion and Analysis of Financial 11
Condition and Results of Operations
Item 3. Quantitative and Qualitative Disclosures about Market Risk 13
PART II. OTHER INFORMATION
Item 1. Legal Proceedings 13
Item 6. Exhibits and Reports on Form 8-K 14
SIGNATURES 15
</TABLE>
2
<PAGE>
FACTORS AFFECTING FORWARD-LOOKING STATEMENTS
This Quarterly Report on Form 10-Q includes "forward-looking
statements" within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The
words "anticipate", "believe", "expect", "estimate", "project" and similar
expressions are intended to identify forward-looking statements. Such statements
are subject to certain risks, uncertainties and assumptions. Should one or more
of these risks or uncertainties materialize, or should underlying assumptions
prove incorrect, actual results may vary materially from those anticipated,
believed, expected, estimated or projected. These risks and uncertainties
include technological uncertainty and risks associated with the
commercialization of the Company's technology, the Company's history of
operating losses and uncertainty of future profitability, manufacturing risks
and uncertainties, uncertainty of market acceptance of the Company's technology,
the Company's reliance on environmental regulations, uncertainties as to the
protection offered by the Company's patents and proprietary technology, the
Company's dependence on collaborations, the Company's need for additional funds,
limited marketing experience and dependence on key personnel, government
regulations, competition and other risks and uncertainties described in the
Company's filings with the Securities and Exchange Commission. For additional
discussion of such risks, uncertainties and assumptions ("Cautionary
Statements"), see "Item 2. Management's Discussion and Analysis of Financial
Condition and Results of Operations - Liquidity and Capital Resources" included
elsewhere in this report and "Item 1. Business - Risk Factors" in the Company's
Annual Report on Form 10-K for the year ended December 31, 1999 ("1999 Form
10-K"). All subsequent written and oral forward-looking statements attributable
to the Company or persons acting on its behalf are expressly qualified in their
entirety by the Cautionary Statements.
3
<PAGE>
PART I. FINANCIAL INFORMATION
ITEM 1. FINANCIAL STATEMENTS
The following unaudited financial statements have been prepared
pursuant to the rules and regulations of the Securities and Exchange Commission.
Certain information and note disclosures normally included in annual financial
statements prepared in accordance with generally accepted accounting principles
have been condensed or omitted pursuant to those rules and regulations, although
the Company believes that the disclosures made herein are adequate to make the
information presented not misleading. These financial statements should be read
in conjunction with the 1999 Form 10-K.
The information presented in the accompanying financial statements is
unaudited, but in the opinion of management, reflects all adjustments (which
include only normal recurring adjustments) necessary to present fairly such
information.
4
<PAGE>
ENERGY BIOSYSTEMS CORPORATION
BALANCE SHEETS
<TABLE>
<CAPTION>
March 31, December 31,
2000 1999
----------- -------------
(Unaudited)
ASSETS
<S> <C> <C>
Current assets:
Cash and cash equivalents $3,257,933 $2,510,274
Short-term investments 1,500,000 3,445,199
Prepaid expenses and other current assets 482,501 143,014
----------- -------------
Total current assets 5,240,434 6,098,487
Furniture, equipment and leasehold improvements, net 903,664 926,684
Intangible and other assets, net 1,127,897 1,038,927
----------- -------------
Total assets $7,271,995 $8,064,098
=========== =============
LIABILITIES & STOCKHOLDERS' EQUITY
Current liabilities:
Accounts payable and accrued liabilities $ 354,329 $ 327,150
Short term capital lease 11,288 --
Deferred revenue 180,000 180,000
Note payable 73,067 --
----------- -------------
Total current liabilities 618,684 507,150
Long term capital lease 69,224 --
Stockholders' equity:
Series B Convertible Preferred Stock, $0.01 par value
(liquidation value $35,105,000; 760,000 shares authorized,
395,700 and 519,400 shares, respectively, issued and
outstanding) 22,257,840 28,100,250
Common Stock, $0.01 par value (30,000,000 shares
authorized, 7,016,029 and 6,572,135 shares,
respectively, issued and outstanding) 70,160 65,721
Additional paid-in capital 61,005,385 54,470,252
Accumulated deficit (76,749,298) (75,079,275)
----------- -------------
Total stockholders' equity 6,584,087 7,556,948
----------- -------------
Total liabilities and stockholders' equity $7,271,995 $8,064,098
=========== =============
</TABLE>
The accompanying notes are an integral part of these financial statements.
5
<PAGE>
STATEMENTS OF OPERATIONS
(UNAUDITED)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
-----------------------------
2000 1999
----------- -------------
<S> <C> <C>
REVENUES:
Sponsored research revenues $ 287,697 $ 510,873
Interest and investment income 70,976 21,146
----------- -------------
Total revenues 358,673 532,019
----------- -------------
COSTS AND EXPENSES:
Research and development 1,006,463 1,601,376
General and administrative 471,588 547,048
----------- -------------
Total costs and expenses 1,478,051 2,148,424
----------- -------------
NET LOSS $(1,119,378) $(1,616,405)
=========== ============
NET LOSS PER COMMON SHARE -
basic and diluted $ (0.27) $ (1.15)
=========== ============
SHARES USED IN COMPUTING
NET LOSS PER COMMON
SHARE - basic and diluted 6,645,402 2,179,882
=========== ============
</TABLE>
The accompanying notes are an integral part of these financial statements.
6
<PAGE>
STATEMENTS OF CASH FLOWS
(UNAUDITED)
<TABLE>
<CAPTION>
Three Months Ended
March 31,
-----------------------------
2000 1999
----------- -------------
<S> <C> <C>
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss $(1,119,378) $(1,616,405)
Adjustments to reconcile net loss to net cash provided by
(used in) operating activities:
Depreciation and amortization 116,787 202,811
Issuance of common stock for services -- 5,000
Changes in assets and liabilities:
Increase in prepaid expenses and other current assets (339,487) (145,420)
Increase (decrease) in accounts payable and accrued
liabilities 27,179 (57,336)
----------- -------------
Net cash used in operating activities (1,314,899) (1,611,350)
----------- -------------
CASH FLOWS FROM INVESTING ACTIVITIES:
Capital expenditures (84,767) (2,700)
Patent expenditures (97,970) (74,666)
Net sale of investments 1,945,199 --
----------- -------------
Net cash provided by (used in) investing activities 1,762,462 (77,366)
----------- -------------
CASH FLOWS FROM FINANCING ACTIVITIES:
Capital lease obligations 80,512 --
Issuance (payments) on notes payable 73,067 (28,136)
Issuance of stock and warrants 146,517 --
----------- -------------
Net cash provided by (used in) financing activities 300,096 (28,136)
----------- -------------
NET INCREASE (DECREASE) IN CASH AND CASH EQUIVALENTS 747,659 (1,716,852)
CASH AND CASH EQUIVALENTS AT BEGINNING OF PERIOD 2,510,274 2,795,429
----------- -------------
CASH AND CASH EQUIVALENTS AT END OF PERIOD $3,257,933 $1,078,577
=========== =============
</TABLE>
The accompanying notes are an integral part of these financial statements.
7
<PAGE>
NOTES TO FINANCIAL STATEMENTS
MARCH 31, 2000
NOTE 1. BASIS OF PRESENTATION AND SIGNIFICANT ACCOUNTING POLICIES
Energy BioSystems Corporation ("EBC") was incorporated in the State of
Delaware on December 20, 1989, and commenced operations in January 1990. EBC is
a biotechnology company that is applying state-of-the-art directed evolution
techniques to accelerate development and commercialization of biocatalyst-based
processes for petroleum refining and petrochemicals production. EBC's primary
focus to date has been development of biocatalytic desulfurization ("BDS"), a
proprietary process involving the use of enzymes in bacteria to remove sulfur
from petroleum.
EBC has discovered that its proprietary biocatalytic technology may also
provide an economic basis for production of a broad family of industrial
organosulfur chemicals with potential uses in detergent, surfactant, polymer and
adhesive markets. Joint development and testing agreements were executed with
several major chemical companies for detailed evaluation of these products in
specific commercial applications, and EBC is pursuing strategic business
alliances for commercialization of this technology.
In 1999, a program was implemented to rapidly screen mutant strains for
improved performance, and a proprietary directed evolution platform with
gene-shuffling was conceived, designed and implemented to increase the diversity
of strains that are tested. EBC believes that this strategy will greatly
accelerate the development of the BDS commercial biocatalyst. EBC also believes
that many applications exist for its technology in gene-shuffling and
bioprocessing.
The Board of Directors of the Company believes that its current name,
Energy BioSystems Corporation, no longer reflects its commitment to the
development of its gene-shuffling technology and its new focus on the
biotechnology industry and has proposed the Company change its name to Enchira
Biotechnology Corporation. This proposal is contained in the Company's proxy and
will become effective upon approval of shareholders eligible to vote at the
Company's Annual Meeting to be held on June 8, 2000.
On April 27, 2000, the Company received notice from Maxygen Inc.
("Maxygen") that they had elected to seek arbitration under the License and
Development Agreement dated May 19, 1997 between the Company and Maxygen (the
"Agreement"). Maxygen claims that the Company used Maxygen's confidential
information which they allege was provided to the Company under the Agreement to
develop its own RACHITT-TM- directed evolution technology. The Company denies
all allegations of Maxygen and believes that its technology was independently
developed after the collaboration with Maxygen ceased. No date for arbitration
has been set. While the Company believes that there is no merit to the
allegations brought against it by Maxygen, the Company cannot assure that its
defense will be substantially successful, if at all. As with any litigation
the outcome cannot be predicted, however, the Company currently believes it
will not have a material adverse affect on the financial statements.
The accompanying unaudited interim financial statements reflect all
adjustments which, in the opinion of management, are necessary for a fair
presentation of the results for the interim
8
<PAGE>
NOTES TO FINANCIAL STATEMENTS - (CONTINUED)
periods presented. These financial statements should be read in conjunction with
the 1999 Form 10-K.
Revenue Recognition
Sponsored research revenue is recognized based on the percentage of total
research payments to be received in relation to the total research and
development costs to be incurred under specific research agreements. In December
1999, the Securities and Exchange Commission ("SEC") issued Staff Accounting
Bulletin 101, "Revenue Recognition in Financial Statements" ("SAB 101") which
provides guidance related to revenue recognition based on interpretations and
practices followed by the SEC. SAB 101 is effective the second fiscal quarter of
fiscal years beginning after December 15, 1999, and requires companies to report
any changes in revenue recognition as a cumulative change in accounting
principle at the time of implementation. EBC is currently evaluating the impact
of SAB 101 on its financial position and results of operations and no changes in
revenue recognition are anticipated.
Net Loss Per Common Share
Net loss per share has been computed by dividing the net loss, which has
been increased for periodic accretion and accrued dividends on the Series B
Convertible Preferred Stock issued in February and March 1997, by the weighted
average number of shares of common stock outstanding during the period.
Use of Estimates
The preparation of financial statements in conformity with generally
accepted accounting principles requires management to make estimates and
assumptions that affect the reported amounts of assets and liabilities and
disclosures of contingent assets and liabilities at the date of the financial
statements and the reported amounts of revenues and expenses during the
reporting period. Actual results could differ from those estimates.
NOTE 2. SERIES B CONVERTIBLE PREFERRED STOCK
Shares of Series B Preferred Stock are convertible into shares of common
stock at an adjusted conversion price equal to $20.06 per share, subject to
certain adjustments. The Series B Preferred Stock may be redeemed by the Company
under certain circumstances after February 26, 1999 and is required to be
redeemed, subject to certain limitations, on February 26, 2002 at a redemption
price of $50.00 per share, plus accrued and unpaid dividends. It is the
Company's intent, however, to redeem the Series B Preferred Stock for common
stock. Accordingly, the Series B Preferred Stock is included in stockholders'
equity. During the first quarter of 2000, 123,700 shares of Series B Preferred
Stock were converted to 308,322 shares of common stock.
9
<PAGE>
NOTES TO FINANCIAL STATEMENTS - (CONTINUED)
As of March 31, 2000, 306,400 shares of Series B Preferred Stock had been
converted to 522,011 shares of common stock and all deferred dividends accrued
on the Series B Preferred Stock converted were paid in cash or common stock at
the time of conversion. The Company elected to deferred payment of the May 1,
2000 dividend.
10
<PAGE>
ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS
OF OPERATIONS
OVERVIEW
Since its inception in December 1989, the Company has devoted
substantially all resources to its research and development. To date, all of the
Company's revenues have resulted from interest and investment income and
sponsored research payments from collaborative agreements. The Company has
incurred cumulative net losses since inception and expects to incur substantial
losses for at least the next several years, due primarily to its research and
development activities and the development of its organosulfur compounds;
directed evolution technology; and biocatalyst, fermentation and bioreactor
programs. The Company expects that losses will fluctuate from quarter to quarter
and that such fluctuations may be substantial. As of March 31, 2000, the
Company's accumulated deficit was $76,749,298.
RESULTS OF OPERATIONS
The Company had total revenues for the three months ended March 31, 2000
and 1999 of $358,673 and $532,019, respectively. The decrease of $173,346 in
total revenues was attributable to decreases in sponsored research revenues
offset in part by an increase in interest and investment income. The Company had
sponsored research revenues of $287,697 during the first three months of 2000 as
compared to $510,873 during the first three months of 1999. The decrease of
$223,176 in sponsored research revenues resulted primarily from the decrease in
sponsored research revenues from a Department of Energy ("DOE") grant to
$241,374 in the first three months of 2000 compared to $510,873 in the first
three months of 1999.
The Company had interest and investment income of $70,976 and $21,146 for
the first three months of 2000 and 1999, respectively. The increase in
investment income of $49,830 resulted primarily from an increase in the
available cash from which interest and other investment income are generated.
The Company had research and development expenses for the three months
ended March 31, 2000 and 1999 of $1,006,463 and $1,601,376, respectively. The
decrease in research and development expenses of $594,913 for the three months
ended March 31, 2000 as compared to the corresponding prior year period resulted
primarily from a reduction in research and development personnel in the first
quarter of 1999. The Company expects its research and development expenses to
increase in 2000, as it fully develops the high through-put screening
capabilities used in directed evolution technology.
The Company had general and administrative expenses for the three months
ended March 31, 2000 and 1999 of $471,588 and $547,048, respectively. The
decrease in general and administrative expenses of $75,460 for the three months
ended March 31, 2000 as compared to the corresponding prior year period resulted
primarily from a reduction in general and administrative personnel in the first
quarter of 1999. The Company expects its general and administrative expenses to
increase as it adds business development personnel and additional expenses
associated with commercialization of its directed evolution technology.
11
<PAGE>
LIQUIDITY AND CAPITAL RESOURCES
As of March 31, 2000, 306,400 shares of Series B Preferred Stock had been
converted to 522,011 shares of common stock. Dividends on the Series B Preferred
Stock are cumulative from the date of the initial closing, February 27, 1997,
and are payable in cash or common stock of the Company, or a combination
thereof, at an annual rate equal to (i) $4.00 per share to the extent the
dividend is paid in cash and (ii) $4.50 per share to the extent the dividend is
paid in common stock. The Company elected to defer payment of the May 1, 1999,
November 1, 1999 and May 1, 2000 dividends in accordance with the Series B
Preferred Stock Agreement. At the time of conversion of Series B Preferred Stock
to common stock accrued, unpaid dividends are paid either in cash or common
stock.
For the three months ended March 31, 2000, the Company used $1,314,899 in
operating activities, incurred $182,737 in capital and patent expenditures and
provided $300,096 in financing activities. At March 31, 2000, the Company had
cash, cash equivalents and short-term investments totaling $4,757,933 and
working capital of $4,621,750.
The Company expects to incur substantial additional research and
development expenses, including expenses associated with its directed evolution
technology; organosulfur compounds; and biocatalyst, fermentation and bioreactor
development. In addition, the Company is subject to cost sharing arrangements
under various collaboration agreements.
In October 1999, the DOE approved the third year of funding to the Company
of approximately $1.0 million, for a program dedicated to the development of a
BDS application for gasoline. Through March 31, 2000 the Company has recognized
$2.2 million in sponsored research revenue from the grant, of which $241,374 was
receivable at March 31, 2000.
The Company has experienced negative cash flow from operations since its
inception and has funded its activities to date primarily from equity financings
and sponsored research revenues. The Company will continue to require
substantial funds to continue its research and development activities and to
market, sell and commercialize its technology. The Company believes that its
available cash, investments and interest income will be adequate to fund its
operations through mid 2001.
The Company's capital requirements will depend on many factors, including
the problems, delays, expenses and complications frequently encountered by
companies developing and commercializing new technologies; the progress of the
Company's research and development activities; timing of environmental
regulations; the rate of technological advances; determinations as to the
commercial potential of the Company's technology under development; the status
of competitive technology; the outcome of the Maxygen dispute; the establishment
of biocatalyst manufacturing capacity or third-party manufacturing arrangements;
the establishment of collaborative relationships; the success of the Company's
sales and marketing programs; the cost of filing, prosecuting and defending and
enforcing patents and intellectual property rights and of defending the Maxygen
claims; and other changes in economic, regulatory or competitive conditions in
the Company's planned business. Estimates about the adequacy of funding for the
Company's activities are based upon certain assumptions, including assumptions
that the research and development programs relating to the Company's technology
can be conducted at projected costs and that progress towards the
commercialization of its technology will be timely
12
<PAGE>
and successful. There can be no assurance that changes in the Company's
research and development plans, acquisitions or other events will not result
in accelerated or unexpected expenditures. To satisfy its capital
requirements, the Company may seek additional funding through various
alternatives that include: an equity financing, government funding, and
alliances with chemical companies and corporate partners. There can be no
assurance that any such funding will be available to the Company on favorable
terms or at all. If adequate funds are not available when needed, the Company
may be required to delay, scale back or eliminate some or all of its research
and product development programs. If the Company is successful in obtaining
additional financing, the terms of such financing may have the effect of
diluting or adversely affecting the holdings or the rights of the holders of
the Company's Common Stock.
In April 2000, the Company received notice from Maxygen, Inc. that they had
elected to seek arbitration under the License and Development Agreement dated
May 19, 1997 between the Company and Maxygen. See Item 1 to Part II -- Legal
Proceedings. The cost of defending such arbitration could be quite substantial
and could greatly and adversely effect the Company's projections for working
capital. In addition, the uncertainty surrounding the outcome of the arbitration
as well as the delay in bringing such matter to conclusion could materially
adversely affect the Company's ability to secure additional capital on a timely
basis or at all. Further, should the arbitrator's decision be adverse to the
Company, the business of the Company would be materially adversely affected.
ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURE ABOUT MARKET RISK
None
PART II. OTHER INFORMATION
ITEM 1. LEGAL PROCEEDINGS
On April 27, 2000, the Company received notice from Maxygen Inc. that they
had elected to seek arbitration under the License and Development Agreement
dated May 19, 1997 between the Company and Maxygen. Maxygen claims that the
Company used Maxygen's confidential information which they allege was provided
to the Company under the Agreement to develop its own RACHITT-TM- directed
evolution technology. The Company denies all allegations of Maxygen and believes
that its technology was independently developed after the collaboration with
Maxygen ceased. No date for arbitration has been set. While the Company believes
that there is no merit to the allegations brought against it by Maxygen, the
Company cannot assure that its defense will be substantially successful, if at
all. If the Company is not successful, its business could be materially and
adversely affected and could be required to enter into cross license agreements,
pay a substantial amount in damages or otherwise have its proprietary rights in
directed evolution technology adversely affected.
<TABLE>
<CAPTION>
ITEM 6. EXHIBITS AND REPORTS ON FORM 8-K
<S> <C>
a. Exhibits
11.1 Statement regarding Computation of Per Share Earnings.
27.1 Financial Data Schedule.
13
<PAGE>
b. Reports on Form 8-K
</TABLE>
On February 7, 2000, the Company filed a Current Report on Form 8-K
reporting an event under Item 5.
14
<PAGE>
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this report to be signed on its behalf by the
undersigned, thereunto duly authorized.
Energy BioSystems Corporation
By: /s/ Peter P. Policastro
------------------------------------------------
Peter P. Policastro
Chief Executive Officer and President
Date: May 11, 2000
By: /s/ Paul G. Brown III
------------------------------------------------
Paul G. Brown III
Vice President, Finance and Administration and
Chief Financial Officer
Date: May 11, 2000
15
<PAGE>
EXHIBIT 11.1
STATEMENT REGARDING COMPUTATION OF PER SHARE EARNINGS
The following schedules reflect the information used in calculating the
number of shares in the computation of net loss per share for each of the
periods set forth in the Statements of Operations.
<PAGE>
BASIC AND DILUTED EARNINGS PER SHARE COMPUTATION
THREE MONTHS ENDED MARCH 31, 2000
<TABLE>
<CAPTION>
Weighted Average Shares Outstanding:
<S> <C> <C> <C> <C><C>
TOTAL # DAYS
SHARES OUTSTANDING
6,572,135 x 4 = 26,288,540
6,574,135 x 7 = 46,018,945
6,576,135 x 15 = 98,642,025
6,578,135 x 14 = 92,093,890
6,591,135 x 1 = 6,591,135
6,596,135 x 6 = 39,576,810
6,624,189 x 8 = 52,993,512
6,629,189 x 1 = 6,629,189
6,691,762 x 6 = 40,150,572
6,706,762 x 1 = 6,706,762
6,723,424 x 3 = 20,170,272
6,734,224 x 14 = 94,279,136
6,734,917 x 4 = 26,939,668
6,772,512 x 6 = 40,635,072
7,016,029 x 1 = 7,016,029
------- -------------
91 = 604,731,557
======= =============
604,731,557 / 91 - 6,645,402
==========
</TABLE>
<TABLE>
<CAPTION>
Loss Per Share:
<S> <C> <C> <C>
Net Loss plus dividend accrual
plus accretion of offering costs $(1,777,300) = $(0.27)
- --------------------------------- ------------- ==========
Weighted Avg. Shares 6,645,402
</TABLE>
<PAGE>
BASIC AND DILUTED EARNINGS PER SHARE COMPUTATION
THREE MONTHS ENDED MARCH 31, 1999
<TABLE>
<CAPTION>
Weighted Average Shares Outstanding:
<S> <C> <C> <C> <C><C>
TOTAL # DAYS
SHARES OUTSTANDING
2,179,124 x 19 = 41,403,356
2,179,713 x 30 = 65,391,390
2,180,358 x 41 = 89,394,678
------- -------------
273 196,189,424
======= =============
196,189,424 / 90 = 2,179,882
==========
</TABLE>
<TABLE>
<CAPTION>
Loss Per Share:
<S> <C> <C> <C>
Net Loss plus dividend accrual
plus accretion of offering costs $(2,503,843) = $(1.15)
- --------------------------------- ------------- ==========
Weighted Avg. Shares 2,179,882
</TABLE>
<TABLE> <S> <C>
<PAGE>
<ARTICLE> 5
<LEGEND>
THIS SCHEDULE CONTAINS SUMMARY FINANCIAL INFORMATION EXTRACTED FROM THE
FINANCIAL STATEMENTS INCLUDED IN THE REGISTRANT'S QUARTERLY REPORT ON FORM 10-Q
FOR THE THREE MONTHS ENDED MARCH 31, 2000 AND IS QUALIFIED IN ITS ENTIRETY BY
REFERENCE TO SUCH FINANCIAL STATEMENTS.
</LEGEND>
<S> <C>
<PERIOD-TYPE> 3-MOS
<FISCAL-YEAR-END> DEC-31-2000
<PERIOD-START> JAN-01-2000
<PERIOD-END> MAR-31-2000
<CASH> 3,257,933
<SECURITIES> 0
<RECEIVABLES> 268,777
<ALLOWANCES> 0
<INVENTORY> 16,055
<CURRENT-ASSETS> 5,240,434
<PP&E> 6,674,059
<DEPRECIATION> 5,770,395
<TOTAL-ASSETS> 7,271,995
<CURRENT-LIABILITIES> 618,684
<BONDS> 0
0
22,257,840
<COMMON> 70,160
<OTHER-SE> 61,005,385
<TOTAL-LIABILITY-AND-EQUITY> 7,271,995
<SALES> 0
<TOTAL-REVENUES> 358,673
<CGS> 0
<TOTAL-COSTS> 1,478,051
<OTHER-EXPENSES> 0
<LOSS-PROVISION> 0
<INTEREST-EXPENSE> 0
<INCOME-PRETAX> (1,119,378)
<INCOME-TAX> 0
<INCOME-CONTINUING> (1,119,378)
<DISCONTINUED> 0
<EXTRAORDINARY> 0
<CHANGES> 0
<NET-INCOME> (1,119,378)
<EPS-BASIC> (0.27)
<EPS-DILUTED> (0.27)
</TABLE>
